Cyltezo Pen 40 Mg/0.4 Ml Starter Pack - shortage update: What patients need to know in 2026

Cyltezo Pen 40 Mg/0.4 Ml Starter Pack: 2026 Shortage Update

If you rely on Cyltezo Pen 40 Mg/0.4 Ml Starter Pack to manage your autoimmune condition, you may have noticed it's become harder to find. Whether you're dealing with pharmacy stockouts, insurance hurdles, or long wait times from specialty pharmacies, you're probably wondering: is Cyltezo actually in shortage?

Here's everything you need to know about Cyltezo availability in 2026 — and what you can do to keep your treatment on track.

Is Cyltezo Still in Shortage?

As of early 2026, Cyltezo Pen 40 Mg/0.4 Ml Starter Pack is not listed on the FDA's official drug shortage database. However, that doesn't mean it's easy to find. Many patients report difficulty filling their prescriptions, especially at retail pharmacies.

The availability challenges with Cyltezo are not a traditional drug shortage caused by manufacturing problems. Instead, they stem from the unique way specialty biologic medications are distributed and the competitive dynamics of the adalimumab biosimilar market.

What's Happening in the Market

Since Humira's patent exclusivity ended, the adalimumab market has become crowded with biosimilars. Pharmacy benefit managers (PBMs) and insurance companies have responded by selecting preferred products based on rebate negotiations. This means:

• Some plans only cover one or two specific adalimumab biosimilars
• Pharmacies stock the products their most common patients need
• Products that aren't "preferred" become harder to access — even when they're not technically in shortage

Cyltezo, despite being the first interchangeable adalimumab biosimilar, has faced stiff competition from products like Amjevita and Hadlima that have secured more favorable PBM contracts.

Why Is Cyltezo Hard to Find?

Several factors contribute to Cyltezo's limited availability at the pharmacy level:

• Specialty distribution: Cyltezo is dispensed primarily through specialty pharmacies, not retail chains
• PBM formulary decisions: Your insurance may prefer a competing adalimumab biosimilar
• Cold-chain requirements: Pharmacies need refrigerated storage for biologics
• Market fragmentation: With many biosimilars available, no single pharmacy stocks all of them

For a more detailed look, read our post on why Cyltezo is so hard to find.

What Does Cyltezo Cost in 2026?

The cost of Cyltezo depends on your insurance coverage:

• Without insurance: Approximately $5,800 to $6,500 for a monthly supply (one 40 mg pen every other week)
• With commercial insurance: $0 to $500 per month, depending on your plan and copay structure
• With copay assistance: Boehringer Ingelheim offers a copay card that may reduce costs to as little as $0 per month for eligible commercially insured patients

Compared to Humira's list price of approximately $6,900 to $7,200 per month, Cyltezo typically offers a 5-15% savings at list price. However, actual out-of-pocket costs depend heavily on your specific insurance plan.

For detailed savings strategies, check out our guide on how to save money on Cyltezo.

Are There New Options in 2026?

Yes. The adalimumab biosimilar market continues to evolve. As of 2026, patients have access to multiple alternatives:

• Amjevita (adalimumab-atto) by Amgen — interchangeable biosimilar
• Hadlima (adalimumab-bwwd) by Samsung Bioepis/Organon
• Hyrimoz (adalimumab-adaz) by Sandoz
• Simlandi (adalimumab-ryvk) by Teva — interchangeable biosimilar
• Yusimry (adalimumab-aqvh) by Coherus BioSciences

These all work the same way as Cyltezo and Humira. If Cyltezo isn't available or affordable through your plan, one of these alternatives may be easier to access. Learn more in our post on alternatives to Cyltezo.

How to Find Cyltezo in Stock Right Now

If you want to stay on Cyltezo, here are the best steps to take:

1. Search on Medfinder

Medfinder shows you real-time pharmacy availability for Cyltezo across specialty and retail pharmacies. It's the fastest way to find a pharmacy that has it in stock.

2. Work With a Specialty Pharmacy

Ask your doctor to send your prescription to a specialty pharmacy that stocks Cyltezo. Most specialty pharmacies offer home delivery with cold-chain shipping. Common options include Accredo, CVS Specialty, and Optum Specialty.

3. Contact Boehringer Ingelheim Patient Support

The manufacturer's patient support program can help you locate a pharmacy, navigate insurance issues, and access copay assistance. Call the number on the Cyltezo website or ask your doctor's office for the contact information.

4. Talk to Your Doctor About Prior Authorization

If your insurance requires prior authorization or has Cyltezo as non-preferred, your doctor can submit a prior authorization or formulary exception request. This process takes a few days to two weeks but can open up access.

Final Thoughts

Cyltezo Pen 40 Mg/0.4 Ml Starter Pack isn't facing a traditional manufacturing shortage in 2026, but it can still be difficult to find due to specialty distribution, insurance restrictions, and market competition. The important thing is to stay on your treatment.

Use Medfinder to check availability, work with your doctor on insurance approvals, and don't hesitate to explore alternative adalimumab products if needed. Your autoimmune condition won't wait — and neither should your access to effective medication.